Tags : Merck & Co


Merck & Co. to Initiate P-II Study of MK-5890 for

Shots: The P-II study will evaluate MK-5890 + Keytruda (pembrolizumab) in patients with sq. and non-sq. NSCLC prior treated with anti-PD-L1 therapy. The study is the part of pembrolizumab umbrella master protocol (MK-3475-U01) In 2014, Merck signed WW license agreement with Aduro to develop & commercialize MK-5890, under which Aduro received $10M as development milestones […]Read More


Merck & Co. Collaborates with Atreca to Identify Novel Antibody

Shots: Atreca to receive up front and retain rights to develop Abs included in the collaboration with Merck while Merck will get a right-of-first negotiation, if Atreca out-licenses its one or more Abs therapies Following target identification, both the companies have the right to advance therapeutic candidates against the targets identified under the collaboration in […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (January 20-24, 2020)

1. Epizyme’s Tazverik (tazemetostat) Receives the US FDA’s Accelerated Approval as the First Therapy for Epithelioid Sarcoma Published: Jan 23, 2020 | Tags: Epizyme, Tazverik, tazemetostat, Receives, US, FDA, Accelerated Approval, First Therapy, Epithelioid Sarcoma 2. Evarsana Signs an Agreement with Evoke Pharma to Commercialize Gimoti in the US Published: Jan 23, 2020 | Tags: Evarsana, Signs, […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (January 06-10, 2020)

Nektar Therapeutics Signs a Clinical Trial Collaboration with Bristol-Myers Squibb Published: Jan 10, 2020 | Tags: Nektar Therapeutics, Signs, Clinical Trial, Collaboration, Bristol-Myers Squibb 2. Eli Lilly to Acquire Dermira for $1.1B Published: Jan 10, 2020 | Tags: Eli Lilly, Acquire, Dermira, $1.1B 3. Bayer Signs a Three Year Multi Target AI-based Agreement with Exscientia to Treat […]Read More


BioMed Collaborates with Merck & Co for Autoimmune Diseases

Shots: BioMed and Merck & Co (MSD outside the United States and Canada) signs an agreement and extends their ongoing collaboration for six joint research projects at BioMed X Innovation Center in Heidelberg, Germany The focus of the agreement is to concentrate on the role of intestinal epithelial barrier in the development and exacerbation of […]Read More


InxMed Signs a Clinical Trial Collaboration with Merck & Co

Shots: InxMed to sponsor the trial while Merck & Co (MSD outside the United States and Canada) will provide pembrolizumab for evaluation in the trial   The focus of the collaboration is to evaluate the combination of InxMed’s IN10018 plus Merck’s pembrolizumab in patients with pancreatic cancer IN10018 (formerly BI853520) is an investigational selective ATP-competitive […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (Dec 30, 2019-Jan 03, 2020)

1. RedHill Terminates its 2014 Deal with Salix Pharmaceuticals for RHB-106 Published: Jan 03, 2019 | Tags: 2014, Deal, RedHill, RHB-106, Salix Pharmaceuticals, Terminates 2. Innate’s Lumoxiti (moxetumomab pasudotox-tdfk) Receives EMA’s MAA to Treat Patients with Relapsed or Refractory Hairy Cell Leukemia Published: Jan 03, 2019 | Tags: EMA, Hairy Cell Leukemia, Innate, Lumoxit, MAA, […]Read More

Top 20

Top Biosimilar Companies with Approved and Pipeline Products in the

Biosimilars are the key alternatives for expensive Biologics therapies and saving millions of dollars of patients spent in the treatment of multiple diseases. Hence physicians are likely to adopt biosimilars “a reference product to biologics” possessing similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. The companies are focusing on […]Read More